Skip to main content
. 2021 Feb 19;52(6):472–475. doi: 10.4103/ijp.IJP_555_18

Table 2.

Comparing the number of patients free of zoster pain in both the study groups at each follow-up

Days Valacyclovir, n (%) Famciclovir, n (%) P*
3 0 0 -
8 6 (20) 6 (20) 1.000
15 16 (53.34) 14 (47) 0.7963
22 18 (60) 16 (53.34) 0.7945
29 24 (80) 18 (60) 0.1590

*P<0.05 significant